公开(公告)号：EP1222202A2

公开(公告)日：2002-07-17

申请号：EP00968795.5

申请日：2000-10-05

申请人： Active Biotech AB

发明人： HANDLEY, Harold, H. ,  HAAPARANTA, Tapio ,  EWALT, Karla, L.

IPC分类号： C07K14/28 ,  C07K14/245 ,  C07K14/25 ,  C07K14/235 ,  C12N15/31 ,  C12N5/10 ,  A61K39/106 ,  A61K39/112 ,  A61K39/10 ,  A61K39/108

CPC分类号： C07K14/245 ,  A61K39/00 ,  C07K14/235 ,  C07K14/25 ,  C07K14/28 ,  Y02A50/472

摘要： A recombinant AB5 B subunit protein including at least one mutation, wherein the mutation alters the number of amino acid residues available for chemical modification as compared to a wild type AB5 B subunit protein, and wherein said recombinant protein retains an effective target ligand bind affinity. For example, specifically designed mutations are produced in the cholera Toxin B subunit (CTB) such that it can still bind with high affinity to its receptor, Gm-1, but can be specifically covalently linked at lysines or cysteines to an immunogen or vaccine. The vaccine produced from this coupling is a mucosal vaccine which has high immunogenicity due to the interaction with the CTB. The vaccine can be produced inexpensively and easily. Alternatively, a technique is disclosed for treating CTB such that non-covalent coupling to a vaccine or immunogen can occur.